SkinBioTherapeutics (SBTX) has announced that it has received regulatory approval to sell its food supplement to alleviate the symptoms associated with psoriasis, AxisBiotix-Ps, into the French market and that marketing of the product there is expected to launch next month.
SkinBioTherapeutics (SBTX) has announced no-one watching o’clock (4:30pm) results for its year ended 30th June 2022, with CEO Stuart Ashman stating “this financial year has been a mixed one for the group”. With the results coming with a potentially £3.5 million equity raise (albeit including an up to £1 million “retail offer”) at 16p per share, we’ve got some other words for it but where does this all leave the company now?
SkinBioTherapeutics(SBTX) has announced results for its half-year ended 31st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.
SkinBioTherapeutics(SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30th June year-end cash totalled £4.6 million. Sounds good.